GenSight Biologics will present one Paper on our second lead product candidate GS030 at EURETINA on March 2, 2019 in Prague.

GS030 is an innovative optogenetic treatment that started a Phase I/II PIONEER clinical trial in Europe and US with patients affected by Retinitis Pigmentosa (RP).

GS030 – Optogenetics in Retinitis Pigmentosa (RP)

Free-Paper Title:  Optogenetics in the clinic: PIONEER: a phase 1/2 open-label, non-randomized, dose-escalation study to evaluate safety and tolerability of GS030 in subjects with retinitis pigmentosa

  • Presenting Author: Katz, Chief Medical Officer, GenSight Biologics, United States
  • Session Title: Quick-Fire Free Papers Session
  • Date/Time: Saturday 02 March 2019, 12:00 pm
  • Room: Clarion Congress Hotel Prague
  • Theme: Miscellaneous